Viloxazine ER (Qelbree^®): A New Non-Stimulant Option in the Treatment of Pediatric Attention-Deficit/Hyperactivity Disorder

The current article provides a brief overview for psychiatric-mental health nurse practitioners of viloxazine extended-release (Qelbree^(®)) for the treatment of pediatric attention-deficit/hyperactivity disorder. [Journal of Psychosocial Nursing and Mental Health Services, 60(7), 7-9.].

via https://pubmed.ncbi.nlm.nih.gov/35858173/?utm_source=no_user_agent&utm_medium=rss&utm_campaign=None&utm_content=1L37KAMf2b_g4WEK3LmdFuKZu9pO3cN7u4ZmO9PPCPeBLMIw1q&fc=None&ff=20220804010903&v=2.17.7